SARS1

Across TCGA pan-cancer cohorts, SARS1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SARS1 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SARS1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SARS1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

PDAC, UCEC, and LSCC are the cancer types where SARS1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.467	0.876	.001	19	view →
UCEC	DFS	Tertile	All	0.902	1.000	.023	14	view →
LSCC	DFS	Quartile	All	0.923	0.758	.020	5	view →
GBM	DFS	Tertile	All	0.446	0.270	.046	2	view →
LUAD	OS	Quartile	II,III,IV	0.910	1.000	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SARS1–PDAC (DFS)

Open the PDAC breakdown →